VISION Trial: Indocyanine green fluorescence vs standard assessment for flap perfusion in head and neck reconstruction

Phase 4, randomised, single-blind trial of indocyanine green in head and neck cancer (HNC) and head and neck trauma-related defects (2 arms), sponsored by Region Skåne. Primary endpoint: Incidence of partial flap loss requiring surgical intervention within 1 month. Planned start Sep 2026; status: authorised.